Switch theme
Sign up to access all valuation multiples
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
2016
408
LTM Revenue $59.1M
LTM EBITDA -$559M
$37.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vir Biotechnology has a last 12-month revenue of $59.1M and a last 12-month EBITDA of -$559M.
In the most recent fiscal year, Vir Biotechnology achieved revenue of $63.7M and an EBITDA of -$538M.
Vir Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vir Biotechnology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $39.5M | $63.7M | XXX | XXX | XXX |
| Gross Profit | $1.4B | $36.7M | XXX | XXX | XXX |
| Gross Margin | 3631% | 58% | XXX | XXX | XXX |
| EBITDA | -$665M | -$538M | XXX | XXX | XXX |
| EBITDA Margin | -1683% | -844% | XXX | XXX | XXX |
| Net Profit | $516M | -$615M | XXX | XXX | XXX |
| Net Margin | 1306% | -965% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 29, 2025, Vir Biotechnology's stock price is $6.
Vir Biotechnology has current market cap of $845M, and EV of $37.5M.
See Vir Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.5M | $845M | XXX | XXX | XXX | XXX | $-3.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 29, 2025, Vir Biotechnology has market cap of $845M and EV of $37.5M.
Vir Biotechnology's trades at 0.6x LTM EV/Revenue multiple, and -0.1x LTM EBITDA.
Analysts estimate Vir Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vir Biotechnology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $37.5M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -1.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVir Biotechnology's NTM/LTM revenue growth is -54%
Vir Biotechnology's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Vir Biotechnology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vir Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vir Biotechnology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 61% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -844% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -898% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 795% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 965% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vir Biotechnology acquired XXX companies to date.
Last acquisition by Vir Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Vir Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vir Biotechnology founded? | Vir Biotechnology was founded in 2016. |
| Where is Vir Biotechnology headquartered? | Vir Biotechnology is headquartered in United States of America. |
| How many employees does Vir Biotechnology have? | As of today, Vir Biotechnology has 408 employees. |
| Who is the CEO of Vir Biotechnology? | Vir Biotechnology's CEO is Dr. Marianne De Backer, PhD. |
| Is Vir Biotechnology publicy listed? | Yes, Vir Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Vir Biotechnology? | Vir Biotechnology trades under VIR ticker. |
| When did Vir Biotechnology go public? | Vir Biotechnology went public in 2019. |
| Who are competitors of Vir Biotechnology? | Similar companies to Vir Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vir Biotechnology? | Vir Biotechnology's current market cap is $845M |
| What is the current revenue of Vir Biotechnology? | Vir Biotechnology's last 12-month revenue is $59.1M. |
| What is the current EBITDA of Vir Biotechnology? | Vir Biotechnology's last 12-month EBITDA is -$559M. |
| What is the current EV/Revenue multiple of Vir Biotechnology? | Current revenue multiple of Vir Biotechnology is 0.6x. |
| What is the current EV/EBITDA multiple of Vir Biotechnology? | Current EBITDA multiple of Vir Biotechnology is -0.1x. |
| What is the current revenue growth of Vir Biotechnology? | Vir Biotechnology revenue growth between 2023 and 2024 was 61%. |
| Is Vir Biotechnology profitable? | Yes, Vir Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
